| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
2.51M |
$23.1M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
2.09M |
$19.3M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Actuate Co-Invest II, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
2.64M |
$13.2M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
1.26M |
$11.6M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Clinical Opportunity Fund, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
980K |
$9.03M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
573K |
$5.28M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Actuate Co-Invest III, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
1.02M |
$5.12M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
526K |
$4.84M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Fund I, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
799K |
$4M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
405K |
$3.73M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Fund III NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
384K |
$3.53M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Fund III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
308K |
$2.83M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Fund I QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
301K |
$2.77M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Actuate Co-Invest I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
300K |
$2.76M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Fund II, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
468K |
$2.34M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund I QP, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
436K |
$2.18M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Azitra Co-Invest I, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
427K |
$2.13M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund III NT, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
405K |
$2.02M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund III, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
313K |
$1.57M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
196K |
$1.37M |
$7.00 |
Jun 27, 2025 |
Directly held by Bios 2024 Co-Invest, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
131K |
$1.21M |
$9.21 |
Jun 27, 2025 |
Directly held by Bios Fund II NT, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
373K |
$1.15M |
$3.09 |
Jun 13, 2025 |
By Bios Fund II QP, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
323K |
$999K |
$3.09 |
Jun 13, 2025 |
By Bios Fund I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
84.9K |
$782K |
$9.21 |
Jun 27, 2025 |
Directly held by BP Directors, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
137K |
$685K |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund II NT, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
2.02M |
$667K |
$0.33 |
Jun 18, 2025 |
By Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
69.4K |
$639K |
$9.21 |
Jun 27, 2025 |
Directly held by Circle K Invesco, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
189K |
$584K |
$3.09 |
Jun 13, 2025 |
By Bios Fund I QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
61K |
$562K |
$9.21 |
Jun 27, 2025 |
Directly held by Aaron G.L. Fletcher |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
3.73M |
$559K |
$0.15 |
May 2, 2025 |
By Bios Fund III QP, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
1.42M |
$470K |
$0.33 |
Jun 18, 2025 |
By Bios Memory SPV I, LP |
| Azitra Inc |
10%+ Owner |
Common Stock |
91K |
$455K |
$5.00 |
Jun 21, 2023 |
Directly held by Circle K Invesco, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
114K |
$353K |
$3.09 |
Jun 13, 2025 |
By Bios Fund II, LP |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
1.88M |
$281K |
$0.15 |
May 2, 2025 |
By Bios Fund II QP, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
500K |
$165K |
$0.33 |
Jun 18, 2025 |
By Bios Clinical Opportunity Fund, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
50K |
$154K |
$3.09 |
Jun 13, 2025 |
By Bios Fund II NT, LP |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
997K |
$150K |
$0.15 |
May 2, 2025 |
By BIOS Incysus Co-Invest I, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
419K |
$138K |
$0.33 |
Jun 18, 2025 |
By Bios Fund I, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
385K |
$127K |
$0.33 |
Jun 18, 2025 |
By Bios Memory SPV II, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
327K |
$108K |
$0.33 |
Jun 18, 2025 |
By Bios Fund III NT, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
310K |
$102K |
$0.33 |
Jun 18, 2025 |
By Bios Fund III, LP |
| Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
26.1K |
$101K |
$3.86 |
Jun 13, 2025 |
By BP Directors, LP |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
602K |
$90.3K |
$0.15 |
May 2, 2025 |
By Bios Fund III, NT, LP |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
574K |
$86.2K |
$0.15 |
May 2, 2025 |
By Bios Fund II, LP |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
571K |
$85.6K |
$0.15 |
May 2, 2025 |
By Bios Fund III, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
256K |
$84.4K |
$0.33 |
Jun 18, 2025 |
By Bios Fund II QP, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
245K |
$80.9K |
$0.33 |
Jun 18, 2025 |
By Bios Fund I QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
8.06K |
$74.2K |
$9.21 |
Jun 27, 2025 |
Directly held by KF Legacy Trust U/A/D December 7, 2016 |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
8.06K |
$74.2K |
$9.21 |
Jun 27, 2025 |
Directly held by MF Legacy Trust U/A/D December 7, 2016 |
| IN8BIO, INC. |
10%+ Owner |
Common Stock |
251K |
$37.7K |
$0.15 |
May 2, 2025 |
By Bios Fund II NT, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
78.3K |
$25.8K |
$0.33 |
Jun 18, 2025 |
By Bios Fund II, LP |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
48.5K |
$16K |
$0.33 |
Jun 18, 2025 |
Indirect |
| COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
34.2K |
$11.3K |
$0.33 |
Jun 18, 2025 |
By Bios Fund II NT, LP |
| IN8BIO, INC. |
10%+ Owner |
Pre-Funded Warrants |
2.43M |
|
|
May 2, 2025 |
By Bios Clinical Opportunity Fund, LP |
| IN8BIO, INC. |
10%+ Owner |
Series C Warrant |
709K |
|
|
May 2, 2025 |
By Bios Clinical Opportunity Fund, LP |
| IN8BIO, INC. |
10%+ Owner |
Stock Option |
85K |
|
|
May 2, 2025 |
Indirect |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
71.4K |
|
|
Jun 27, 2025 |
Directly held by Bios 2024 Co-Invest, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
31.9K |
|
|
Aug 12, 2024 |
Directly held by BP Directors, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
15K |
|
|
Aug 12, 2024 |
Directly held by Aaron G.L. Fletcher |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Convertible Note |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Clinical Opportunity Fund, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series A Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series A Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund I QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest I, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III QP, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
| ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
| Azitra Inc |
10%+ Owner |
Convertible Notes |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III, LP |
| Azitra Inc |
10%+ Owner |
Convertible Notes |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III NT, LP |
| Azitra Inc |
10%+ Owner |
Convertible Notes |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III QP, LP |
| Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Azitra Co-Invest I, LP |
| Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II, LP |
| Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II NT, LP |
| Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II QP, LP |
| Azitra Inc |
10%+ Owner |
Series A Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund I, LP |
| Azitra Inc |
10%+ Owner |
Series A Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund I QP, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III NT, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III QP, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II NT, LP |
| Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II QP, LP |
| IN8BIO, INC. |
10%+ Owner |
Series A Warrant |
0 |
|
|
May 2, 2025 |
By Bios Clinical Opportunity Fund, LP |
| IN8BIO, INC. |
10%+ Owner |
Series B Warrant |
0 |
|
|
May 2, 2025 |
By Bios Clinical Opportunity Fund, LP |